clinical trial · NCT03899155
Pan Tumor Rollover Study
Bristol-Myers Squibb·phase2·recruiting·n = 1,500
CancerNivolumabIpilimumabCabozantinibTrametinibRelatlimabNivolumab + RelatlimabCapecitabineBevacizumab
brief summary
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
started
Aug 9, 2019
primary completion
Aug 25, 2029
completion
Aug 25, 2029
last updated
Jul 2, 2026
official title
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol